메뉴 건너뛰기




Volumn 29, Issue 3, 2009, Pages 201-205

Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; FLUOXETINE; GLUCOCORTICOID; LAMOTRIGINE; NEUROLEPTIC AGENT; NORFLUOXETINE; OLANZAPINE; PHENYTOIN; QUETIAPINE; RIFAMPICIN; VALPROIC ACID;

EID: 67649262125     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181a497f1     Document Type: Editorial
Times cited : (17)

References (28)
  • 1
    • 67649282667 scopus 로고    scopus 로고
    • Guidance for Industry: drug interaction studies - study design, data analysis and implications for dosing and labeling. http://www.fda.gov/cber/ gdlns/interactstud.htm Draft published in September 2006. Last accessed 6 October 2006.
    • Guidance for Industry: drug interaction studies - study design, data analysis and implications for dosing and labeling. http://www.fda.gov/cber/ gdlns/interactstud.htm Draft published in September 2006. Last accessed 6 October 2006.
  • 2
    • 54449098492 scopus 로고    scopus 로고
    • Preparation of scientific reports on pharmacokinetic drug interaction studies
    • Greenblatt DJ. Preparation of scientific reports on pharmacokinetic drug interaction studies. J Clin Psychopharmacol. 2008;28(4):369-373.
    • (2008) J Clin Psychopharmacol , vol.28 , Issue.4 , pp. 369-373
    • Greenblatt, D.J.1
  • 3
    • 8044237061 scopus 로고
    • Clinical biostatistics I. A new name and some other changes of the guard
    • Feinstein AR. Clinical biostatistics I. A new name and some other changes of the guard. Clin Pharmacol Ther. 1970;11:135-148.
    • (1970) Clin Pharmacol Ther , vol.11 , pp. 135-148
    • Feinstein, A.R.1
  • 5
    • 0035032568 scopus 로고    scopus 로고
    • Interindividual variability in inhibition and induction of cytochrome P450 enzymes
    • Lin JH, Lu AYH. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 2001;41:535-567.
    • (2001) Annu Rev Pharmacol Toxicol , vol.41 , pp. 535-567
    • Lin, J.H.1    Lu, A.Y.H.2
  • 6
    • 29544449443 scopus 로고    scopus 로고
    • Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19
    • de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75-85.
    • (2006) Psychosomatics , vol.47 , Issue.1 , pp. 75-85
    • de Leon, J.1    Armstrong, S.C.2    Cozza, K.L.3
  • 7
    • 62449286261 scopus 로고    scopus 로고
    • DNA microarray technology in the clinical environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 genotyping
    • de Leon J, Susce MT, Johnson M, et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 Test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009;14(1):19-34.
    • (2009) CNS Spectr , vol.14 , Issue.1 , pp. 19-34
    • de Leon, J.1    Susce, M.T.2    Johnson, M.3
  • 8
    • 34248597277 scopus 로고    scopus 로고
    • A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels
    • de Leon J, Susce MT, Pan RM, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007;40(3):93-102.
    • (2007) Pharmacopsychiatry , vol.40 , Issue.3 , pp. 93-102
    • de Leon, J.1    Susce, M.T.2    Pan, R.M.3
  • 10
    • 30344457586 scopus 로고    scopus 로고
    • A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    • Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113.
    • (2006) Clin Pharmacol Ther , vol.79 , Issue.1 , pp. 103-113
    • Sim, S.C.1    Risinger, C.2    Dahl, M.L.3
  • 11
    • 34248596149 scopus 로고    scopus 로고
    • The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19
    • de Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19. J Clin Psychopharmacol. 2007;27(3):241-245.
    • (2007) J Clin Psychopharmacol , vol.27 , Issue.3 , pp. 241-245
    • de Leon, J.1
  • 12
    • 44849135619 scopus 로고    scopus 로고
    • Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables
    • Diaz FJ, Santero V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41(3):81-91.
    • (2008) Pharmacopsychiatry , vol.41 , Issue.3 , pp. 81-91
    • Diaz, F.J.1    Santero, V.2    Spina, E.3
  • 13
    • 47749087003 scopus 로고    scopus 로고
    • Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model
    • Botts S, Diaz FJ, Santoro V, et al. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1453-1458.
    • (2008) Prog Neuropsychopharmacol Biol Psychiatry , vol.32 , Issue.6 , pp. 1453-1458
    • Botts, S.1    Diaz, F.J.2    Santoro, V.3
  • 15
    • 33845988396 scopus 로고    scopus 로고
    • Metabolic drug interactions with newer antipsychotics: A comparative review
    • Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4-22.
    • (2007) Basic Clin Pharmacol Toxicol , vol.100 , Issue.1 , pp. 4-22
    • Spina, E.1    de Leon, J.2
  • 16
    • 0037345011 scopus 로고    scopus 로고
    • Glucuronidation enzyme genes and psychiatry
    • de Leon J. Glucuronidation enzyme genes and psychiatry. Int J Neuropsychopharmacol. 2003;6(1):57-72.
    • (2003) Int J Neuropsychopharmacol , vol.6 , Issue.1 , pp. 57-72
    • de Leon, J.1
  • 17
    • 32944471001 scopus 로고    scopus 로고
    • So many studies, too few subjects: Establishing functional relevance of genetic polymorphisms on pharmacokinetics
    • Williams JA, Johnson K, Paulauskis J, et al. So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Psychopharmacol. 2006;46(3):258-264.
    • (2006) J Clin Psychopharmacol , vol.46 , Issue.3 , pp. 258-264
    • Williams, J.A.1    Johnson, K.2    Paulauskis, J.3
  • 18
    • 0035103586 scopus 로고    scopus 로고
    • Fluoxetine pharmacokinetics and effects on CYP2C19 in young and elderly volunteers
    • Harvey AT, Preskorn S. Fluoxetine pharmacokinetics and effects on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001;21(2):161-166.
    • (2001) J Clin Psychopharmacol , vol.21 , Issue.2 , pp. 161-166
    • Harvey, A.T.1    Preskorn, S.2
  • 19
    • 0035195659 scopus 로고    scopus 로고
    • Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy
    • Brunswick DJ, Amsterdam JD, Fawcett J, et al. Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy. J Clin Psychopharmacol. 2001;21(6):616-618.
    • (2001) J Clin Psychopharmacol , vol.21 , Issue.6 , pp. 616-618
    • Brunswick, D.J.1    Amsterdam, J.D.2    Fawcett, J.3
  • 20
    • 0031800865 scopus 로고    scopus 로고
    • A mechanistic approach to antiepileptic drug interactions
    • Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998;32(5):554-563.
    • (1998) Ann Pharmacother , vol.32 , Issue.5 , pp. 554-563
    • Anderson, G.D.1
  • 21
    • 0842266734 scopus 로고    scopus 로고
    • Psychopharmacology: Atypical antipsychotic dosing: the effect of co-medication with anticonvulsants
    • de Leon J. Psychopharmacology: atypical antipsychotic dosing: the effect of co-medication with anticonvulsants. Psychiatr Serv. 2004;55(2):125-128.
    • (2004) Psychiatr Serv , vol.55 , Issue.2 , pp. 125-128
    • de Leon, J.1
  • 22
    • 2442495384 scopus 로고    scopus 로고
    • Psychopharmacology: Atypical antipsychotic dosing: the effect of smoking and caffeine
    • de Leon J. Psychopharmacology: atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv. 2004;55(5):491-493.
    • (2004) Psychiatr Serv , vol.55 , Issue.5 , pp. 491-493
    • de Leon, J.1
  • 23
    • 0035142323 scopus 로고    scopus 로고
    • The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine
    • Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001;21(1):89-93.
    • (2001) J Clin Psychopharmacol , vol.21 , Issue.1 , pp. 89-93
    • Wong, Y.W.1    Yeh, C.2    Thyrum, P.T.3
  • 24
    • 67649279470 scopus 로고    scopus 로고
    • Astra Zeneca Pharmaceuticals. Seroquel (Quetiapaine Fumarate Tablets): Highlights of Prescribing Information. Wilmington, DE: Astra Zeneca Pharmaceuticals; 2008.
    • Astra Zeneca Pharmaceuticals. Seroquel (Quetiapaine Fumarate Tablets): Highlights of Prescribing Information. Wilmington, DE: Astra Zeneca Pharmaceuticals; 2008.
  • 26
    • 0032807123 scopus 로고    scopus 로고
    • Possible interaction between warfarin and quetiapine
    • Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine. J Clin Psychopharmacol. 1999;19(4):382-383.
    • (1999) J Clin Psychopharmacol , vol.19 , Issue.4 , pp. 382-383
    • Rogers, T.1    de Leon, J.2    Atcher, D.3
  • 27
    • 67649279469 scopus 로고    scopus 로고
    • Drug interactions
    • Shorvon S, Perucca E, Engel J, eds, 3rd ed. Oxford: Wiley-Blackwell Publishing Ltd;
    • Spina E. Drug interactions. In: Shorvon S, Perucca E, Engel J, eds. Treatment of Epilepsy. 3rd ed. Oxford: Wiley-Blackwell Publishing Ltd; 2009:361-377.
    • (2009) Treatment of Epilepsy , pp. 361-377
    • Spina, E.1
  • 28
    • 12844256482 scopus 로고    scopus 로고
    • Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers
    • Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract. 2005;11(1):5-15.
    • (2005) J Psychiatr Pract , vol.11 , Issue.1 , pp. 5-15
    • Preskorn, S.H.1    Silkey, B.2    Shah, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.